4,035 Shares in DaVita Inc. (NYSE:DVA) Acquired by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH bought a new position in DaVita Inc. (NYSE:DVA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,035 shares of the company's stock, valued at approximately $603,000.

Other hedge funds have also recently modified their holdings of the company. United Capital Financial Advisors LLC boosted its position in DaVita by 2.6% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock worth $361,000 after purchasing an additional 62 shares in the last quarter. Freedom Investment Management Inc. boosted its position in DaVita by 3.6% during the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after purchasing an additional 62 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock worth $133,000 after purchasing an additional 68 shares in the last quarter. Coppell Advisory Solutions LLC boosted its position in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after purchasing an additional 100 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in DaVita by 16.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 712 shares of the company's stock worth $107,000 after purchasing an additional 101 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Price Performance

Shares of NYSE:DVA traded up $1.36 during midday trading on Tuesday, hitting $135.77. The company had a trading volume of 995,687 shares, compared to its average volume of 821,222. DaVita Inc. has a twelve month low of $131.76 and a twelve month high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The stock has a market cap of $10.25 billion, a price-to-earnings ratio of 12.64, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The business's 50-day simple moving average is $143.42 and its 200-day simple moving average is $152.51.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter last year, the firm earned $2.26 earnings per share. The business's revenue for the quarter was up 5.0% on a year-over-year basis. On average, research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Barclays increased their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Truist Financial reduced their target price on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $164.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.